http://aggregates.owt.com/aggs/poster-presentation.xml Poster Presentation News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNE4RYcjbCzDtcIYKeigwMWJLoxh9w&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52778836915596&ei=_GFaVYiADcOimALA0oCwCA&url=http://www.marketwatch.com/story/xencors-xmab5871-program-to-be-featured-in-poster-presentation-at-european-league-against-rheumatism-eular-2015-annual-meeting-2015-05-11 Mon, 11 May 2015 12:03:11 GMT <br /><a href="http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNE4RYcjbCzDtcIYKeigwMWJLoxh9w&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52778836915596&ei=_GFaVYiADcOimALA0oCwCA&url=http://www.marketwatch.com/story/xencors-xmab5871-program-to-be-featured-in-poster-presentation-at-european-league-against-rheumatism-eular-2015-annual-meeting-2015-05-11">Xencor's XmAb®5871 Program to be Featured in Poster Presentation at ...</a><br />MarketWatch<br />MONROVIA, Calif., May 11, 2015 /PRNewswire/ -- Xencor, Inc. XNCR, +1.92% a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, ...<br /><br /><a class="p" href="http://news.google.com/news/more?ncl=dcNneiQesZ6XO2M&authuser=0&ned=us">and more »</a> http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNF-brdBghGpHgKUdAdYgHuwUGMOgw&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52778845451763&ei=_GFaVYiADcOimALA0oCwCA&url=http://www.businesswire.com/news/home/20150518005750/en/Presentation-International-Headache-Congress-shows-electroCore%25E2%2580%2599s-chronic Mon, 18 May 2015 11:37:40 GMT <br /><a href="http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNF-brdBghGpHgKUdAdYgHuwUGMOgw&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52778845451763&ei=_GFaVYiADcOimALA0oCwCA&url=http://www.businesswire.com/news/home/20150518005750/en/Presentation-International-Headache-Congress-shows-electroCore%25E2%2580%2599s-chronic">Presentation at International Headache Congress shows electroCore's chronic ...</a><br />Business Wire (press release)<br />The poster presentation was based on the successful PREVA study, which involved 97 patients at ten sites across Europe. The patients were randomised into two arms - one using the gammaCore device plus the standard of care, and the other the standard of ...<br /><br /><a class="p" href="http://news.google.com/news/more?ncl=dVV0Wwwea-NK8VM&authuser=0&ned=us">and more »</a> http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNGFIa7dHYyKpGVzLTCwoyjRhFE1lw&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52778845476371&ei=_GFaVYiADcOimALA0oCwCA&url=http://www.marketwatch.com/story/portola-pharmaceuticals-announces-upcoming-data-presentation-on-dual-kinase-inhibitor-cerdulatinib-at-american-society-of-clinical-oncology-asco-annual-meeting-2015-05-18 Mon, 18 May 2015 12:07:31 GMT <br /><a href="http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNGFIa7dHYyKpGVzLTCwoyjRhFE1lw&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52778845476371&ei=_GFaVYiADcOimALA0oCwCA&url=http://www.marketwatch.com/story/portola-pharmaceuticals-announces-upcoming-data-presentation-on-dual-kinase-inhibitor-cerdulatinib-at-american-society-of-clinical-oncology-asco-annual-meeting-2015-05-18">Portola Pharmaceuticals Announces Upcoming Data Presentation on Dual ...</a><br />MarketWatch<br />SOUTH SAN FRANCISCO, Calif., May 18, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals PTLA, +1.21% today announced that it will present updated safety and efficacy data from the Phase 1 part of its ongoing Phase 1/2a proof-of-concept study of ...<br /><br /><a class="p" href="http://news.google.com/news/more?ncl=dN1id4XXbkfJOEM&authuser=0&ned=us">and more »</a>